申请人:AstraZeneca AB
公开号:US10040789B2
公开(公告)日:2018-08-07
A compound of Formula (I):
or a pharmaceutically acceptable salt thereof, is described. Q can be pyridazin-3-yl, 6-fluoropyridazin-3-yl; R1 can be H; R2 and R3 can each independently be C1-C6 alkyl, or R2 and R3 taken together are —(CH2)3—; or R1 and R2 taken together can be —(CH2)2— and R3 can be —CH3; R4 halo, —CH3, —OCH3, —OCHF2, —OCF3, or —CN; and n can be 0, 1, or 2. The compound of formula (I) can inhibit glutaminase, e.g., GLS1.
式 (I) 的化合物:
或其药学上可接受的盐。Q可以是哒嗪-3-基、6-氟哒嗪-3-基;R1可以是H;R2和R3可以各自独立地是C1-C6烷基,或R2和R3合起来是-(CH2)3-;或R1和R2合起来可以是-(CH2)2-,R3可以是-CH3;R4卤代、-CH3、-OCH3、-OCHF2、-OCF3或-CN;n可以是0、1或2。式(I)化合物可抑制谷氨酰胺酶,如 GLS1。